AU1435492A - Aptamer specific for biomolecules and method of making - Google Patents

Aptamer specific for biomolecules and method of making

Info

Publication number
AU1435492A
AU1435492A AU14354/92A AU1435492A AU1435492A AU 1435492 A AU1435492 A AU 1435492A AU 14354/92 A AU14354/92 A AU 14354/92A AU 1435492 A AU1435492 A AU 1435492A AU 1435492 A AU1435492 A AU 1435492A
Authority
AU
Australia
Prior art keywords
aptamer
target
oligonucleotides
oligonucleotide
aptamers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14354/92A
Other languages
English (en)
Inventor
Louis C Bock
Linda C Griffin
Steven Krawczyk
John A Latham
Daryl Dean Muenchau
John J. Toole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of AU1435492A publication Critical patent/AU1435492A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/974—Thrombin
AU14354/92A 1991-02-21 1992-02-21 Aptamer specific for biomolecules and method of making Abandoned AU1435492A (en)

Applications Claiming Priority (20)

Application Number Priority Date Filing Date Title
US658849 1984-10-09
US659114 1984-10-09
US659103 1984-10-09
US65998191A 1991-02-21 1991-02-21
US65911491A 1991-02-21 1991-02-21
US65879691A 1991-02-21 1991-02-21
US65910391A 1991-02-21 1991-02-21
US65998091A 1991-02-21 1991-02-21
US65911391A 1991-02-21 1991-02-21
US65884991A 1991-02-21 1991-02-21
US659980 1991-02-21
US659113 1991-02-21
US658796 1991-02-21
US659981 1991-02-21
US74487091A 1991-08-14 1991-08-14
US74521591A 1991-08-14 1991-08-14
US744870 1991-08-14
US745215 1991-08-14
US78792191A 1991-11-06 1991-11-06
US787921 1991-11-06

Publications (1)

Publication Number Publication Date
AU1435492A true AU1435492A (en) 1992-09-15

Family

ID=27581306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14354/92A Abandoned AU1435492A (en) 1991-02-21 1992-02-21 Aptamer specific for biomolecules and method of making

Country Status (6)

Country Link
EP (1) EP0572529A4 (fr)
JP (1) JPH06508022A (fr)
AU (1) AU1435492A (fr)
CA (1) CA2104698A1 (fr)
IE (1) IE920562A1 (fr)
WO (1) WO1992014843A1 (fr)

Families Citing this family (279)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869641A (en) * 1990-06-11 1999-02-09 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of CD4
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5789163A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
US5686592A (en) * 1990-06-11 1997-11-11 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US6465189B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Systematic evolution of ligands by exponential enrichment: blended selex
US6124449A (en) * 1990-06-11 2000-09-26 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands and inhibitors
WO1996034876A1 (fr) * 1995-05-04 1996-11-07 Nexstar Pharmaceuticals, Inc. Complexes de ligands d'acide nucleique
US5780228A (en) * 1990-06-11 1998-07-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US5654151A (en) * 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5712375A (en) * 1990-06-11 1998-01-27 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5723289A (en) * 1990-06-11 1998-03-03 Nexstar Pharmaceuticals, Inc. Parallel selex
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5668264A (en) * 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6610841B1 (en) 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US5693502A (en) * 1990-06-11 1997-12-02 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5705337A (en) * 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5789157A (en) * 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5635615A (en) * 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6083696A (en) * 1990-06-11 2000-07-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands exponential enrichment: blended selex
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US6346611B1 (en) 1990-06-11 2002-02-12 Gilead Sciences, Inc. High affinity TGfβ nucleic acid ligands and inhibitors
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US6331394B1 (en) 1991-06-10 2001-12-18 Gilead Sciences, Inc. Nucleic acid ligands to integrins
US5811533A (en) * 1990-06-11 1998-09-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5972599A (en) * 1990-06-11 1999-10-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
US5707796A (en) * 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US6569620B1 (en) 1990-06-11 2003-05-27 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5766853A (en) * 1990-06-11 1998-06-16 Nexstar Pharmaceuticals, Inc. Method for identification of high affinity nucleic acid ligands to selectins
US5763566A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5629155A (en) * 1990-06-11 1997-05-13 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to immunoglobulin E (IgE)
US5622828A (en) * 1990-06-11 1997-04-22 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to secretory phospholipase A2 (sPLA2)
US6177557B1 (en) 1990-06-11 2001-01-23 Nexstar Pharmaceuticals, Inc. High affinity ligands of basic fibroblast growth factor and thrombin
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US5650275A (en) * 1990-06-11 1997-07-22 Nexstar Pharmacueticals Inc Target detection method using spectroscopically detectable nucleic acid ligands
US5861254A (en) * 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US6696252B2 (en) 1990-06-11 2004-02-24 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US6001988A (en) * 1990-06-11 1999-12-14 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands to lectins
US6030776A (en) * 1990-06-11 2000-02-29 Nexstar Pharmaceuticals, Inc. Parallel SELEX
US5683867A (en) * 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5846713A (en) * 1990-06-11 1998-12-08 Nexstar Pharmaceuticals, Inc. High affinity HKGF nucleic acid ligands and inhibitors
US5688935A (en) * 1990-06-11 1997-11-18 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5962219A (en) 1990-06-11 1999-10-05 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-selex
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US6759392B1 (en) 1990-06-11 2004-07-06 Gilead Sciences, Inc. High affinity RNA ligands of basic fibroblast growth factor
US5853984A (en) * 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5874557A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5795721A (en) * 1990-06-11 1998-08-18 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of ICP4
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5637682A (en) * 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. High-affinity oligonucleotide ligands to the tachykinin substance P
US5648214A (en) * 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US6261774B1 (en) 1990-06-11 2001-07-17 Gilead Sciences, Inc. Truncation selex method
US5641629A (en) * 1990-06-11 1997-06-24 Nexstar Pharmacueticals Inc Spectroscopically detectable nucleic acid ligands
US6127119A (en) * 1990-06-11 2000-10-03 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands of tissue target
US5837456A (en) * 1990-06-11 1998-11-17 Nexstar Pharmaceuticals, Inc. High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones
US5763177A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5763173A (en) * 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US5864026A (en) * 1990-06-11 1999-01-26 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US5756287A (en) * 1990-06-11 1998-05-26 Nexstar Pharmaceuticals, Inc. High affinity HIV integrase inhibitors
US5731144A (en) * 1990-06-11 1998-03-24 Nexstar Pharmaceuticals, Inc. High affinity TGFβ nucleic acid ligands
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5674685A (en) * 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6762290B1 (en) 1999-07-29 2004-07-13 Gilead Sciences, Inc. High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors
WO1996040717A1 (fr) * 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Ligands de cytokines a acide nucleique et d'une affinite elevee
US6028186A (en) * 1991-06-10 2000-02-22 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of cytokines
EP0648281A4 (fr) * 1991-09-10 1997-06-04 Jack D Love Amplification de cibles et de signaux d'adn/arn.
AU3250093A (en) 1991-12-12 1993-07-19 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
EP0668931B1 (fr) * 1992-09-29 2006-01-04 Gilead Sciences, Inc. Ligands d'acide nucleique et procedes de production
US6306598B1 (en) * 1992-11-13 2001-10-23 Regents Of The University Of California Nucleic acid-coupled colorimetric analyte detectors
US5599917A (en) * 1994-03-17 1997-02-04 Pharmagenics, Inc. Inhibition of interferon-γ with oligonucleotides
WO1995003406A2 (fr) * 1993-07-19 1995-02-02 Gen-Probe Incorporated Augmentation de l'inhibition oligonucleotidique de la production proteique, de la proliferation cellulaire et/ou de la multiplication d'agents pathogenes de maladie infectieuse
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
US5998142A (en) * 1993-09-08 1999-12-07 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
JPH09506629A (ja) * 1993-12-17 1997-06-30 キュビッチョッティ，ロジャー・エス ヌクレオチドに支配された生体分子および多分子薬物の集合並びに装置
EP0754238A4 (fr) * 1994-04-05 1998-01-28 Pharmagenics Inc Determination et identification de composes actifs dans une bibliotheque de composes
US7153948B2 (en) 1994-04-25 2006-12-26 Gilead Sciences, Inc. High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF)
US6682886B1 (en) 1994-04-28 2004-01-27 Gilead Sciences, Inc. Bivalent binding molecules of 7 transmembrane G protein-coupled receptors
US5882941A (en) * 1994-05-04 1999-03-16 Massachusette Institute Of Technology Programmable genotoxic agents and uses therefor
US6500669B1 (en) 1994-05-04 2002-12-31 Massachusetts Institute Of Technology Programmable genotoxic agents and uses therefor
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US6048698A (en) * 1994-09-20 2000-04-11 Nexstar Pharmaceuticals, Inc. Parallel SELEX™
US5998596A (en) * 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US5753787A (en) * 1995-04-10 1998-05-19 Yale University Nucleic acids encoding ancylostoma secreted protein
AU732961B2 (en) * 1995-05-03 2001-05-03 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
ATE276266T1 (de) * 1995-05-03 2004-10-15 Gilead Sciences Inc Nukleinsäureliganden für gewebeziele
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
EP1741780A3 (fr) 1995-06-02 2007-03-28 Gilead Sciences, Inc. Ligands oligonucléotidiques ayant une affinité élevée pour les facteurs de croissance
US5723594A (en) * 1995-06-07 1998-03-03 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
EP0840739A4 (fr) * 1995-06-07 2006-02-01 Gilead Sciences Inc Ligands d'acide nucleique a haute affinite pour les lectines
US6699843B2 (en) 1995-06-07 2004-03-02 Gilead Sciences, Inc. Method for treatment of tumors using nucleic acid ligands to PDGF
US6111095A (en) 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6183967B1 (en) 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
JP4335975B2 (ja) * 1995-06-07 2009-09-30 ギリード・サイエンシズ・インコーポレーテッド Ｄｎａポリメラーゼに対する結合・阻害核酸リガンド
AU701106B2 (en) 1995-06-07 1999-01-21 Promega Biosciences, Inc. Novel carbamate-based cationic lipids
DE19543750C2 (de) * 1995-11-24 1997-10-23 Crinos Industria Farmaco Cathepsin G inhibierende Aptamere
US6537776B1 (en) 1999-06-14 2003-03-25 Diversa Corporation Synthetic ligation reassembly in directed evolution
CA2630098A1 (fr) 1996-02-01 1997-08-07 Gilead Sciences, Inc. Acides nucleiques ligands a forte affinite pour les proteines du systeme complementaire
JP2000507097A (ja) * 1996-03-12 2000-06-13 ベーリンガー マンハイム ゲーエムベーハー アルギニンに結合する単離されたｒｎａ分子およびその使用
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
US6838238B1 (en) * 1996-10-17 2005-01-04 Invitrogen Corporation Morphatides: novel shape and structure libraries
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US5871924A (en) * 1997-01-27 1999-02-16 Nexstar Pharmaceuticals, Inc. Method for the production of ligands capable of facilitating aminoacyl-RNA synthesis
DE69835516D1 (de) 1997-05-16 2006-09-21 Exact Sciences Corp Elektrophoretische analyse von molekülen mit immobilisierten sonden
AU8505898A (en) * 1997-07-22 1999-02-16 Genitrix, Llc Nucleic acid compositions and methods of introducing nucleic acids into cells
AU9210498A (en) * 1997-08-29 1999-03-16 Gilead Sciences, Inc. 5',5'-linked oligomers having anti-thrombin activity
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US5989823A (en) 1998-09-18 1999-11-23 Nexstar Pharmaceuticals, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6261783B1 (en) 1997-12-15 2001-07-17 Gilead Sciences, Inc. Homogeneous detection of a target through nucleic acid ligand-ligand beacon interaction
US6180348B1 (en) * 1998-04-20 2001-01-30 Weihua Li Method of isolating target specific oligonucleotide ligands
US6287765B1 (en) * 1998-05-20 2001-09-11 Molecular Machines, Inc. Methods for detecting and identifying single molecules
EP1026243B1 (fr) * 1998-08-14 2006-02-01 Japan Science and Technology Agency Acide nucleique capable de se lier specifiquement a une proteine cible ras
US6423493B1 (en) 1998-10-26 2002-07-23 Board Of Regents The University Of Texas System Combinatorial selection of oligonucleotide aptamers
US6329145B1 (en) 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6280943B1 (en) 1999-06-17 2001-08-28 Gilead Sciences, Inc. 2′-fluoropyrimidine anti-calf intestinal phosphatase nucleic acid ligands
US6780850B1 (en) 1999-06-22 2004-08-24 Triumf Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood
US6387620B1 (en) 1999-07-28 2002-05-14 Gilead Sciences, Inc. Transcription-free selex
US6171795B1 (en) 1999-07-29 2001-01-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to CD40ligand
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
US7005260B1 (en) 2000-01-28 2006-02-28 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
JP2004500109A (ja) 2000-03-22 2004-01-08 クァンタム・ドット・コーポレイション ビーズベースの核酸アッセイにおける半導体ナノクリスタルの使用方法
US20020103349A1 (en) * 2000-05-25 2002-08-01 Asher Nathan Drug-oligonucleotides chimeric molecules
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6376190B1 (en) * 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
AU9630501A (en) * 2000-09-26 2002-04-08 Univ Duke Rna aptamers and methods for identifying the same
EP2085781B2 (fr) 2000-10-06 2020-03-11 Life Technologies Corporation Cellules dotées d'une signature spectrale et leurs procédés de préparation et leur utilisation
US20050059031A1 (en) 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
CA2425605A1 (fr) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Ligands d'acides nucleiques de l'antigene membranaire prostatique specifique
KR20030033007A (ko) 2001-05-31 2003-04-26 코울터 파머수티컬, 인코포레이티드 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제
GB0115841D0 (en) 2001-06-28 2001-08-22 Medical Res Council Ligand
US8030465B2 (en) 2001-06-29 2011-10-04 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
JP2005500058A (ja) 2001-08-17 2005-01-06 ネオーズ テクノロジーズ， インコーポレイテッド シアリル化したオリゴサッカリドの化学的酵素的合成
WO2003029492A1 (fr) * 2001-09-28 2003-04-10 Justin Gallivan Genes metaboliques et procedes et compositions associes
EP1440083B1 (fr) 2001-10-25 2013-01-02 Medical Research Council Molecules
AU2002359761A1 (en) 2001-12-18 2003-06-30 Invenux, Inc. Antibiotic compounds
EP1481090A4 (fr) 2002-02-15 2006-08-09 Somalogic Inc Methodes et reactifs destines a la detection d'une liaison de cibles par des ligands d'acides nucleiques
US20040023415A1 (en) 2002-03-05 2004-02-05 Konstantin Sokolov Biospecific contrast agents
EP1572927A4 (fr) 2002-04-08 2007-10-17 Pioneer Hi Bred Int Procedes d'amelioration de l'exsertion de la soie de mais lorsqu'elle est sujette a des agressions
EP1501929B1 (fr) * 2002-05-06 2013-03-27 Noxxon Pharma AG Acides nucleiques liant le cgrp
AU2003247576A1 (en) * 2002-06-18 2003-12-31 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20040110235A1 (en) 2002-07-25 2004-06-10 David Epstein Regulated aptamer therapeutics
US9303262B2 (en) 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
WO2005003291A2 (fr) 2002-10-16 2005-01-13 Board Of Regents Of The University Of Texas System Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes
US10100316B2 (en) 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
JP2006525796A (ja) 2003-02-27 2006-11-16 イェダ リサーチ アンド デベロップメント カンパニー リミテッド インフルエンザウイルス感染を処置および検出するために有用な核酸分子、ポリペプチド、抗体、およびそれらを含有する組成物
US8017755B2 (en) 2003-05-23 2011-09-13 President And Fellows Of Harvard College RNA-based transcriptional regulators
US7910523B2 (en) 2003-05-23 2011-03-22 Board Of Regents, The University Of Texas System Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
EP1493810A1 (fr) * 2003-06-30 2005-01-05 Gentium S.p.A. Aptamères pour la cathepsine G basés sur de l'ADN
US7803624B2 (en) 2003-09-30 2010-09-28 Cytyc Corporation Automated cytological sample classification
EP1700912B1 (fr) 2003-11-22 2014-10-29 Techno Medica Co., Ltd. Methode de detection d'une molecule cible au moyen d'un aptamere
DK2860251T3 (en) 2004-02-12 2018-06-06 Archemix Llc APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20070066550A1 (en) * 2004-03-05 2007-03-22 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US7579450B2 (en) 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
EP1598428A1 (fr) * 2004-05-18 2005-11-23 Georg Dewald Procédés et trousses pour la détection d'angioedema héréditaire type III
CA2579374A1 (fr) * 2004-09-07 2006-03-30 Archemix Corp. Aptameres au facteur de von willebrand et leur utilisation en tant qu'agents therapeutiques pour des maladies thrombotiques
US7659091B2 (en) 2004-09-21 2010-02-09 Nourheart, Inc. Diagnostic marker
CN101724071A (zh) 2004-10-08 2010-06-09 杜门蒂斯有限公司 抗肿瘤坏死因子受体1的单域抗体及其使用方法
CA2601400A1 (fr) 2005-03-19 2006-09-28 Medical Research Council Ameliorations dans ou concernant le traitement et la prevention d'infections virales
PE20061324A1 (es) 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
TR201902033T4 (tr) 2005-06-30 2019-03-21 Janssen Biotech Inc Anti-IL-23 antikorları, bileşimleri, yöntemleri ve kullanımları.
JP4910195B2 (ja) * 2005-07-05 2012-04-04 株式会社リボミック 免疫グロブリンｇに結合する核酸とその利用法
EP1918372A4 (fr) * 2005-07-05 2009-08-12 Ribomic Inc Acide nucléique capable de se lier à une immunoglobuline g et son utilisation
US7662571B2 (en) 2005-07-14 2010-02-16 Nourheart Inc. Mitochondrial markers of ischemia
BRPI0617546A2 (pt) 2005-09-26 2011-07-26 Medarex Inc conjugado de fÁrmaco-anticorpo, formulaÇço farmacÊutica, mÉtodo para matar uma cÉlula de tumor, mÉtodo para retardar ou interromper o crescimento de um tumor em um sujeito mamÍfero e composto
WO2007059966A1 (fr) * 2005-11-23 2007-05-31 Georg Dewald Détection et traitement de l’œdème de quincke associé à un médicament
MX2008008621A (es) 2005-12-29 2008-11-27 Centocor Inc Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
EP1994171B1 (fr) * 2006-01-17 2015-03-11 Somalogic, Inc. Analyses multiplexées d'échantillons test
US20080008694A1 (en) 2006-07-05 2008-01-10 Elgebaly Salwa A Methods to prevent and treat diseases
PL2041282T3 (pl) * 2006-07-18 2018-07-31 Noxxon Pharma Ag Kwasy nukleinowe wiążące sdf-i
US20100247552A1 (en) 2006-11-10 2010-09-30 Massachusetts Institute Of Technology Pak modulators
JP4698559B2 (ja) * 2006-11-24 2011-06-08 Ｎｅｃソフト株式会社 ウサギ由来のＩｇＧ抗体に結合性を有する核酸分子
US8975026B2 (en) 2007-01-16 2015-03-10 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US20110136099A1 (en) 2007-01-16 2011-06-09 Somalogic, Inc. Multiplexed Analyses of Test Samples
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7964356B2 (en) 2007-01-16 2011-06-21 Somalogic, Inc. Method for generating aptamers with improved off-rates
EP2336314A1 (fr) 2007-07-17 2011-06-22 Somalogic, Inc. Selex et photoselex améliorés
ES2614735T3 (es) 2007-07-23 2017-06-01 Janssen Biotech, Inc. Métodos y composiciones para tratar los trastornos relacionados con fibrosis usando antagonistas de la IL-17
DE102007063902B3 (de) * 2007-08-31 2017-11-23 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
DE102007041476B4 (de) * 2007-08-31 2017-03-30 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamere, die an ein an der Hämostase beteiligtes Zielmolekül binden
US8906700B2 (en) 2007-11-06 2014-12-09 Ambergen, Inc. Methods and compositions for phototransfer
EP2215238A2 (fr) 2007-11-20 2010-08-11 Pioneer Hi-Bred International Inc. Gènes de signalisation d'éthylène de maïs et modulation de ceux-ci pour améliorer la résistance des plantes au stress
EP2268664B1 (fr) 2007-12-03 2017-05-24 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Compositions doc1 et méthodes de traitement du cancer
US20110229498A1 (en) 2008-05-08 2011-09-22 The Johns Hopkins University Compositions and methods for modulating an immune response
EP2116618A1 (fr) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnostic et traitement de la maladie de Kawasaki
US20120003749A1 (en) * 2008-05-21 2012-01-05 Nec Soft, Ltd. Nucleic acid molecule capable of binding to 2,4,6-trinitrophenyl skeleton, method for detecting compound having 2,4,6-trinitrophenyl skeleton using the nucleic acid molecule, and use of the nucleic acid molecule
US8703416B2 (en) 2008-07-17 2014-04-22 Somalogic, Inc. Method for purification and identification of sperm cells
NZ590816A (en) 2008-08-14 2013-02-22 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
PL2356269T3 (pl) 2008-10-31 2016-12-30 Kompozycje białek rusztowania oparte na domenie fibronektyny typu III, sposoby i zastosowania
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
US8716553B2 (en) 2009-03-02 2014-05-06 Pioneer Hi Bred International Inc NAC transcriptional activators involved in abiotic stress tolerance
KR101893011B1 (ko) 2009-04-03 2018-08-30 김성천 압타머 표적화 복합체의 제조방법
TWI578992B (zh) * 2009-04-30 2017-04-21 諾克森製藥股份有限公司 與鐵調節激素（ｈｅｐｃｉｄｉｎ）結合之核酸類
US20100291706A1 (en) 2009-05-15 2010-11-18 Millipore Corporation Dye conjugates and methods of use
US20110035843A1 (en) 2009-08-05 2011-02-10 Pioneer Hi-Bred International, Inc. Novel eto1 genes and use of same for reduced ethylene and improved stress tolerance in plants
WO2011061351A1 (fr) * 2009-11-23 2011-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Aptamères dirigés contre la protéine de matrice 1 de virus de la grippe de type a et leurs utilisations
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
EP2542266A4 (fr) 2010-03-03 2013-10-23 Somalogic Inc Aptamères pouvant se lier à 4-1bb et utilisation associée dans le traitement de maladies et de troubles
US8598140B2 (en) 2010-04-12 2013-12-03 Somalogic, Inc. Aptamers to β-NGF and their use in treating β-NGF mediated diseases and disorders
JP5892608B2 (ja) * 2010-04-19 2016-03-23 国立研究開発法人理化学研究所 機能性核酸の安定化法
US20110306653A1 (en) 2010-05-14 2011-12-15 Tagcyx Biotechnologies Stabilization method of functional nucleic acid
JP2012196197A (ja) * 2011-03-04 2012-10-18 Kanagawa Acad Of Sci & Technol 標的細胞表面の標的分子に特異的に結合する核酸の選択法
EP2497828A1 (fr) * 2011-03-07 2012-09-12 Charité - Universitätsmedizin Berlin Utilisation d'aptamères pour la thérapie et/ou le diagnostic des maladies auto-immunes
US20140194320A1 (en) 2011-08-12 2014-07-10 Tagcyx Bitoecnologies Method for preparing nucleic acid aptamer
CN103906835A (zh) 2011-10-25 2014-07-02 先锋国际良种公司 改变植物细胞壁组成以改善生物燃料生产和青贮饲料可消化性的方法
CN103958683A (zh) * 2011-12-28 2014-07-30 希森美康株式会社 与肾上腺皮质刺激激素结合的分子及其应用
WO2013142255A2 (fr) 2012-03-22 2013-09-26 University Of Miami Agents de liaison multi-spécifiques
US20150337308A1 (en) * 2012-04-11 2015-11-26 Chu De Bordeaux Matrix metalloproteinase 9 (mmp-9) aptamer and uses thereof
BR112015023703A2 (pt) 2013-03-15 2017-07-18 Pioneer Hi Bred Int modulação de expressão de deaminase de acc
WO2014201265A1 (fr) 2013-06-14 2014-12-18 Pacific Biosciences Of California, Inc. Étiquettes de bis-biotinylation
US9765375B2 (en) 2013-06-28 2017-09-19 General Electric Company Methods for developing binding-elements and uses thereof
WO2015097536A2 (fr) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anticorps et fragments anti-vista
ES2683869T3 (es) 2014-05-29 2018-09-28 Quark Pharmaceuticals, Inc. Métodos y composiciones para evitar la lesión por isquemia-reperfusión en órganos
DE102014114834A1 (de) 2014-10-13 2016-04-14 Centrum Für Angewandte Nanotechnologie (Can) Gmbh Nanopartikel enthaltende Polymermizellen in nicht-wässriger Lösung, Methoden zu ihrer Herstellung und ihrer Anwendung
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
EP3436477A2 (fr) 2016-03-29 2019-02-06 Janssen Biotech, Inc. Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23
WO2017175058A1 (fr) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anticorps anti-vista et fragments de ceux-ci, leurs utilisations et leurs procédés d'identification
MX2019000641A (es) 2016-07-15 2019-06-10 Poseida Therapeutics Inc Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso.
JP2019524721A (ja) 2016-07-15 2019-09-05 ポセイダ セラピューティクス， インコーポレイテッド キメラ抗原受容体および使用方法
EP3519049A4 (fr) 2016-09-30 2020-05-27 Janssen Biotech, Inc. Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23
WO2018093841A1 (fr) 2016-11-16 2018-05-24 Janssen Biotech, Inc. Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
KR102596343B1 (ko) * 2016-11-23 2023-10-31 베를린 큐어스 게엠베하 TLR9 활성화의 저해 및/또는 억제에 사용되는 압타머(aptamer)
CN110234351A (zh) 2017-01-30 2019-09-13 詹森生物科技公司 用于治疗活动性银屑病关节炎的抗tnf抗体、组合物和方法
CN110418652A (zh) 2017-02-07 2019-11-05 詹森生物科技公司 用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
AU2018235756A1 (en) 2017-03-13 2019-10-10 Poseida Therapeutics, Inc. Compositions and methods for selective elimination and replacement of hematopoietic stem cells
KR101993427B1 (ko) * 2017-04-26 2019-10-01 주식회사 압타머사이언스 백혈구에 선택적으로 결합하는 압타머 및 이의 용도
CA3072777A1 (fr) 2017-09-08 2019-03-14 Poseida Therapeutics, Inc. Compositions et procedes d'expression genique conditionnelle mediee par un recepteur de ligand chimerique (clr)
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
WO2019150309A1 (fr) 2018-02-02 2019-08-08 Hammack Scott Modulateurs de gpr68 et leurs utilisations pour le traitement et la prévention de maladies
MA52590A (fr) 2018-05-11 2021-03-17 Janssen Biotech Inc Méthodes de traitement de la dépression à l'aide d'anticorps il-23
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
WO2020132396A1 (fr) 2018-12-20 2020-06-25 Poseida Therapeutics, Inc. Compositions de nanotransposons et procédés d'utilisation
WO2020159445A1 (fr) 2019-01-31 2020-08-06 Agency For Science, Technology And Research Inhibiteur cnx/erp57 destiné à être utilisé dans le traitement ou la prévention du cancer
CA3133388A1 (fr) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Procedes de production de compositions d'anticorps anti-tnf
KR20210142002A (ko) 2019-03-14 2021-11-23 얀센 바이오테크 인코포레이티드 항-tnf 항체 조성물을 생성하기 위한 제조 방법
MA55283A (fr) 2019-03-14 2022-01-19 Janssen Biotech Inc Procédés de production de compositions d'anticorps anti-tnf
EA202192459A1 (ru) 2019-03-18 2021-11-25 Янссен Байотек, Инк. Способ лечения псориаза антителом к il12/il23 у субъектов детского возраста
CN110172498B (zh) * 2019-04-28 2022-09-20 广东省微生物研究所（广东省微生物分析检测中心） 一种快速高效分析转录因子及其靶dna结合序列相互作用的方法
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
CN113939531A (zh) 2019-06-03 2022-01-14 詹森生物科技公司 用于治疗银屑病关节炎的抗tnf抗体组合物和方法
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
US20220372105A1 (en) 2019-09-05 2022-11-24 Poseida Therapeutics, Inc. Allogeneic cell compositions and methods of use
KR20220117915A (ko) 2019-12-20 2022-08-24 포세이다 테라퓨틱스, 인크. 항-muc1 조성물 및 사용 방법
EP4118107A1 (fr) 2020-03-11 2023-01-18 Poseida Therapeutics, Inc. Récepteurs stimulateurs chimériques et procédés d'utilisation dans l'activation et la différenciation de lymphocytes t
US20230190811A1 (en) 2020-04-14 2023-06-22 Poseida Therapeutics, Inc. Compositions and methods for use in the treatment of cancer
EP4231999A1 (fr) 2020-10-21 2023-08-30 Poseida Therapeutics, Inc. Compositions et procédés d'administration d'acides nucléiques
CN112778432B (zh) * 2021-02-01 2022-04-22 西藏天虹科技股份有限责任公司 波棱瓜子多糖提取方法
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
WO2023281462A1 (fr) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Procédés de fabrication pour produire des compositions d'anticorps anti-tnf
WO2023060088A1 (fr) 2021-10-04 2023-04-13 Poseida Therapeutics, Inc. Compositions de transposons et leurs procédés d'utilisation
WO2023073615A1 (fr) 2021-10-29 2023-05-04 Janssen Biotech, Inc. Méthodes de traitement de la maladie de crohn avec un anticorps spécifique anti-il23
WO2023141576A1 (fr) 2022-01-21 2023-07-27 Poseida Therapeutics, Inc. Compositions et procédés d'administration d'acides nucléiques
US20230312703A1 (en) 2022-03-30 2023-10-05 Janssen Biotech, Inc. Method of Treating Psoriasis with IL-23 Specific Antibody
US20230374122A1 (en) 2022-05-18 2023-11-23 Janssen Biotech, Inc. Method for Evaluating and Treating Psoriatic Arthritis with IL23 Antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0689014B2 (ja) * 1986-01-21 1994-11-09 興和株式会社 トロンビン結合性物質およびその製法
ES2259800T3 (es) * 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.

Also Published As

Publication number Publication date
IE920562A1 (en) 1992-08-26
WO1992014843A1 (fr) 1992-09-03
EP0572529A1 (fr) 1993-12-08
EP0572529A4 (fr) 1994-11-02
JPH06508022A (ja) 1994-09-14
CA2104698A1 (fr) 1992-08-22

Similar Documents

Publication Publication Date Title
US5756291A (en) Aptamers specific for biomolecules and methods of making
AU1435492A (en) Aptamer specific for biomolecules and method of making
WO1992014842A1 (fr) Aptameres specifiques contre la thrombine et procedes d'utilisation
Xiong et al. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation
KR970002255B1 (ko) 핵산 리간드
US5840867A (en) Aptamer analogs specific for biomolecules
US6369208B1 (en) Capped synthetic RNA, analogs, and aptamers
US6482594B2 (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands
Masud et al. Sialyllactose-binding modified DNA aptamer bearing additional functionality by SELEX
US5763177A (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
JP4176466B2 (ja) 前立腺特異的膜抗原に対する核酸リガンド
Craigie et al. A rapid in vitro assay for HIV DNA integration
CA2622765A1 (fr) Banques ciblees, profilage fonctionnel, laser selex et deselex
AU2002224401A1 (en) Nucleic acid ligands to the prostate specific membrane antigen
AU692185B2 (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
EP1549763B1 (fr) Procédé de sélection d'aptamères
Chen et al. Selective action of 4'-azidothymidine triphosphate on reverse transcriptase of human immunodeficiency virus type 1 and human DNA polymerases. alpha. and. beta.
Florentz et al. Specific valylation identity of turnip yellow mosaic virus RNA by yeast valyl‐tRNA synthetase is directed by the anticodon in a kinetic rather than affinity‐based discrimination
Sharma et al. Purification and characterization of dolichyl-P-mannose: Man5 (GlcNAc) 2-PP-dolichol mannosyltransferase
US20040132067A1 (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
KR20190066811A (ko) 오담(ODAM, Odontogenic Ameloblast-Associated protein)에 특이적으로 결합하는 DNA 앱타머 및 그의 용도
AU728910B2 (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex